
European
Fair Pricing
Network
The European Fair Pricing Network (EFPN) aims for a Europe where every patient has timely and equitable access to all effective anticancer medicines at fair prices. We want sustainable healthcare systems with transparency in pharmaceutical reimbursement decisions, pricing, prices, and R&D costs that swiftly deliver and develop the right treatments for patients.
There have been significant advances in medical treatment of cancer in the past decades, however, access to new therapies remains a challenge. Timely access to products with proven benefit should be assured for patients who need them.
Pharmaceutical spending, and especially spending on novel oncology medicines are rapidly rising. The quantity of expensive cancer medicine entering the European market increases, which challenges economical sustainability. Prices are independent of efficacy, and variate across countries due to private negotiations and rebates.
Transparency is needed throughout the entire system. Starting from research and development all the way to manufacturing, marketing, trade and financing. A transparent system, understandable for both patients and payers, shall ensure timely access to high-quality cost-effective treatments which significantly improve patient outcomes.

Advocacy
The advocacy unit will translate the research findings into policy recommendations in order to shape political decisions on the European and national level. Click here for our key policy messages.
EFPN and ECL recommendations for the EU pharma package trilogue
Each year, approximately 2.7 million people are diagnosed with cancer in Europe – and this number is expected to grow. The EU pharma package is a once-in-a-generation opportunity to reshape EU pharmaceutical legislation, making it more patient-centred by addressing unmet medical needs and ensuring the availability and timely access to life-saving cancer treatments. Despite the medical and technological developments that have resulted in a growing number of cancer medicines being available on the European market, many patients still face unmet medical needs. For these patients, targeted treatments are either unavailable or limited. What’s more, not every patient automatically benefits from innovative treatments, because medicines are unaffordable or simply not available in their country of residence. For example, between 2020 and 2023, cancer patients in Germany had access to 54 out of 56 EU-authorised medicines, while patients in Malta could only access two. The result? Deepened inequalities across Europe. That is why the Association of European Cancer Leagues (ECL) and the European Fair Pricing Network (EFPN) are launching a new position paper to support the ongoing trilogue discussions on the [...]
Transparency
Achieve greater bargaining power for governments in the pricing negotiations with the industry.
Papers
ECL and EFPN recommendations for the revision of the EU legislation on
medicines for rare diseases
Cancer patients need a patient-centered and fit for purpose pharmaceutical system
Recommendations for revision of the EU legislation on medicines for rare diseases
ECL and EFPN recommendations for the revision of the EU legislation on medicines for rare diseases
Accountability
Ensure medicines resulting from publicly funded research are available at an affordable price.
Partner Engagement
Does your organisation value transparency in the pharmaceutical system?
Take the opportunity to become a partner in this international network. As an EFPN partner you can contribute in resources, time or both. We believe that cancer societies have a particular role to play. They are highly respected organizations, act as one of the main funders of cancer research, and focus on the well-being of patients.
Do you believe that increasing transparency will help patients access safe and effective products?
Cancer societies cannot do this on their own. We call on organizations from different fields to join our cause, including researchers, patients, healthcare professionals, philanthropists, and investigative journalists.








